Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | S100B | P04271 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.46 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.46 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110503 | 0.98 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL1110535 | 0.98 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL997022 | 0.98 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL1110554 | 0.98 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL5494223 | 0.96 | ALDH1A1 (0.73) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL28338201 | 0.93 | ALDH1A1 (0.78) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL23850823 | 0.86 | ALDH1A1 (0.89) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL6630046 | 0.86 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL6627622 | 0.85 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNAPKMGAA | |
| SCHEMBL1048147 | 0.85 | KDM4E (0.68) | ALDH1A1KDM4ELMNAPKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024046323-A1 | BENZO FIVE-MEMBERED NITROGEN RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | 山东大学 | 2024-03-07 | — | — | WO | disclosed |
| CN-117143039-A | Benzo five-membered nitrogen ring compound, preparation method and medical application thereof | 山东大学 | 2023-12-01 | — | — | CN | disclosed |
| EP-2666481-B9 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2666481-B9 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2666481-B1 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | ALDH1A1 1025/4885KDM4E 3631/4885LMNA 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.